Veraxa Biotech Holding AG (FRA:J8L0) Shares Outstanding (EOP): 141.41 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J8L0 Veraxa Biotech Holding AG FRA:J8L0
13 GF Score
Price €1.62
! 2 Warning Signs
View Full Analysis

What is Veraxa Biotech Holding AG Shares Outstanding (EOP)?

Veraxa Biotech Holding AG FRA:J8L0 -2.06% 13 Shares Outstanding (EOP) is 141.41 Mil as of Dec. 2025. GuruFocus rates FRA:J8L0 with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Veraxa Biotech Holding AG's shares outstanding for the quarter that ended in Dec. 2025 was 141.41 Mil.

Veraxa Biotech Holding AG's quarterly shares outstanding stayed the same from Jun. 2025 (141.41 Mil) to Dec. 2025 (141.41 Mil).

Veraxa Biotech Holding AG's annual shares outstanding stayed the same from Dec. 2024 (141.41 Mil) to Dec. 2025 (141.41 Mil).


Veraxa Biotech Holding AG  (FRA:J8L0) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Veraxa Biotech Holding AG Shares Outstanding (EOP) Related Terms


Veraxa Biotech Holding AG Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Veraxa Biotech Holding AG's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veraxa Biotech Holding AG Shares Outstanding (EOP) Chart

Veraxa Biotech Holding AG Annual Data
Trend Dec23 Dec24 Dec25
Shares Outstanding (EOP)
141.41 141.41 141.41

Veraxa Biotech Holding AG Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) 141.41 141.41 141.41 141.41 141.41

FRA:J8L0 vs TTRX, IRD, IFRX: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Veraxa Biotech Holding AG's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veraxa Biotech Holding AG Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veraxa Biotech Holding AG's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Veraxa Biotech Holding AG's Shares Outstanding (EOP) falls into.


FRA:J8L0
13GF Score
Veraxa Biotech Holding AG FRA:J8L0
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veraxa Biotech Holding AG Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 141.41 Mil mean?
Veraxa Biotech Holding AG (FRA:J8L0) has a Shares Outstanding (EOP) of 141.41 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Veraxa Biotech Holding AG and its competitors.
Is Veraxa Biotech Holding AG's Shares Outstanding (EOP) too high?
Veraxa Biotech Holding AG's current Shares Outstanding (EOP) is 141.41 Mil. Overall, Veraxa Biotech Holding AG has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Veraxa Biotech Holding AG's Shares Outstanding (EOP) compare to TTRX and IRD?
Veraxa Biotech Holding AG's Shares Outstanding (EOP) of 141.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Veraxa Biotech Holding AG and its competitors. Veraxa Biotech Holding AG's current Shares Outstanding (EOP) is 141.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veraxa Biotech Holding AG stock overvalued right now?
Veraxa Biotech Holding AG (FRA:J8L0) has a current Shares Outstanding (EOP) of 141.41 Mil. The current Shares Outstanding (EOP) is 141.41 Mil. Veraxa Biotech Holding AG's overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Veraxa Biotech Holding AG (FRA:J8L0), the current Shares Outstanding (EOP) is 141.41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veraxa Biotech Holding AG Business Description

Other Exchanges VRXA:USA
Address Talacker 35, Zurich, CHE, 8001
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
13GF Score

Get the complete analysis for FRA:J8L0

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.62
Price